SCHEMBL5355269

SCHEMBL5355269

CC(C)(C)OC(=O)[C@@H]1C[C@H]1c1ccccc1F

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 3/20 0.44
KDM1B Q8NB78 1/20 0.44
HTR2C P28335 1/20 0.42
HTR2B P41595 1/20 0.42
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
GPR88 Q9GZN0 1/20 0.39
PDE5A O76074 1/20 0.38
GAA P10253 2/20 0.36
ALDH1A1 P00352 1/20 0.36
TSHR P16473 1/20 0.36
MAPK1 P28482 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
TDP1 Q9NUW8 1/20 0.35
HSD17B2 P37059 1/20 0.35
HDAC4 P56524 2/20 0.35
PTGDR2 Q9Y5Y4 1/20 0.35
MAOB P27338 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5355273 1.00 KDM1A (0.44) KDM1AKDM1BHTR2CHTR2BMEN1
SCHEMBL5355276 1.00 KDM1A (0.44) KDM1AKDM1BHTR2CHTR2BMEN1
SCHEMBL5345772 0.83 KDM1A (0.47) KDM1AKDM1BHTR2CHTR2BMEN1
SCHEMBL26088648 0.81 CYP2C9 (0.38) KDM1AKMT2AALDH1A1TSHRMAPK1
SCHEMBL30483936 0.81 CYP2C9 (0.38) KDM1AKMT2AALDH1A1TSHRMAPK1
SCHEMBL20555933 0.80 MAPK1 (0.34) KDM1AMEN1KMT2AALDH1A1TSHR
SCHEMBL30483937 0.80 MAPK1 (0.34) KDM1AMEN1KMT2AALDH1A1TSHR
SCHEMBL15805113 0.79 TSHR (0.47) KDM1AKDM1BHTR2CHTR2BGPR88
SCHEMBL19354984 0.79 TSHR (0.47) KDM1AKDM1BHTR2CHTR2BGPR88
SCHEMBL4135293 0.79 TSHR (0.47) KDM1AKDM1BHTR2CHTR2BGPR88

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7217716-B2 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists MERCK & CO., INC. (US) 2007-05-15 US disclosed
US-7217716-B2 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists MERCK & CO., INC. (US) 2007-05-15 US disclosed
US-7217716-B2 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists MERCK & CO., INC. (US) 2007-05-15 US disclosed
US-7053089-B2 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists MERCK & CO., INC. (US) 2006-05-30 US disclosed
EP-1379520-B1 N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS MERCK & CO INC (US) 2006-04-26 EP disclosed
US-20040209889-A1 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists MERCK SHARP & DOHME CORP. 2004-10-21 US disclosed
EP-1379520-A1 N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS Merck & Co., Inc. (US) 2004-01-14 EP disclosed
US-20020165241-A1 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists MERCK SHARP & DOHME LLC 2002-11-07 US disclosed
WO-2002068409-A1 N-SUBSTITUTED NONARYL-HETEROCYCLIC NMDA/NR2B ANTAGONISTS MERCK & CO., INC. (US) 2002-09-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209889-A1 N-substituted nonaryl-heterocyclic nmda/nr2b antagonists GRIN1, GRIN2B, GRIN2A KDM1A 1617/4885KDM1B 2369/4885HTR2C 165/4885
US-20020165241-A1 N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists GRIN1, GRIN2B, GRIN2A KDM1A 1481/4885KDM1B 2057/4885HTR2C 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.